Literature DB >> 16452252

Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Elena D Nosyreva1, Kimberly M Huber.   

Abstract

Fragile X syndrome (FXS), a form of human mental retardation, is caused by loss of function mutations in the fragile X mental retardation gene (FMR1). The protein product of FMR1, fragile X mental retardation protein (FMRP) is an RNA-binding protein and may function as a translational suppressor. Metabotropic glutamate receptor-dependent long-term depression (mGluR-LTD) in hippocampal area CA1 is a form of synaptic plasticity that relies on dendritic protein synthesis. mGluR-LTD is enhanced in the mouse model of FXS, Fmr1 knockout (KO) mice, suggesting that FMRP negatively regulates translation of proteins required for LTD. Here we examine the synaptic and cellular mechanisms of mGluR-LTD in KO mice and find that mGluR-LTD no longer requires new protein synthesis, in contrast to wild-type (WT) mice. We further show that mGluR-LTD in KO and WT mice is associated with decreases in AMPA receptor (AMPAR) surface expression, indicating a similar postsynaptic expression mechanism. However, like LTD, mGluR-induced decreases in AMPAR surface expression in KO mice persist in protein synthesis inhibitors. These results are consistent with recent findings of elevated protein synthesis rates and synaptic protein levels in Fmr1 KO mice and suggest that these elevated levels of synaptic proteins are available to increase the persistence of LTD without de novo protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452252     DOI: 10.1152/jn.01316.2005

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  161 in total

1.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Fragile X mental retardation protein: regulator of specific mRNAs or master regulator of global translation?

Authors:  Denise Cook; Scott A Cameron; Emma V Jones
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.

Authors:  Catherine H Choi; Brian P Schoenfeld; Aaron J Bell; Paul Hinchey; Maria Kollaros; Michael J Gertner; Newton H Woo; Michael R Tranfaglia; Mark F Bear; R Suzanne Zukin; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 4.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 5.  Stem cells and modeling of autism spectrum disorders.

Authors:  Beatriz C G Freitas; Cleber A Trujillo; Cassiano Carromeu; Marianna Yusupova; Roberto H Herai; Alysson R Muotri
Journal:  Exp Neurol       Date:  2012-10-02       Impact factor: 5.330

Review 6.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

7.  Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses.

Authors:  Luyuan Pan; Kendal S Broadie
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

8.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 9.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

Review 10.  Translational control of long-lasting synaptic plasticity and memory.

Authors:  Mauro Costa-Mattioli; Wayne S Sossin; Eric Klann; Nahum Sonenberg
Journal:  Neuron       Date:  2009-01-15       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.